<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111265</url>
  </required_header>
  <id_info>
    <org_study_id>SAHXJTUA01</org_study_id>
    <nct_id>NCT02111265</nct_id>
  </id_info>
  <brief_title>THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients</brief_title>
  <official_title>The Comparison of Efficacy and Safety of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients ——A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Medical Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy and safety of closed-loop target controlled infusion of propofol or
      etomidate at general anesthesia in geriatric patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect Compartment Concentration</measure>
    <time_frame>From the beginning of induction to paitens'left of PACU, up to 4 hours</time_frame>
    <description>The effect compartment concentration of etomidate or propofol are recorded at three time points,including time that patient's loss of eyelash reflex,after 30 minutes of loss of eyelash reflex and when the patient is awake （call then open their eyes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>From the beginning of induction to skin closure, up to 3 hours</time_frame>
    <description>Systolic blood pressure, diastolic blood pressure, heart rate, respiration rate, pulse oxygen saturation recorded every 5 minutes during the operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of drugs</measure>
    <time_frame>From the beginning of induction to skin closure, up to 3 hours</time_frame>
    <description>The amount of narcotics, sedation and muscle relaxation used in general anesthesia arr recorded when the operation is finished.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenal function</measure>
    <time_frame>From entering the operating room to 48 h after induction of anesthesia.</time_frame>
    <description>3 ml blood sample is collected at 5 time points including before induction,30 minutes,2 hours,24 hours, 48 hours after induction;
to examine the concentration of Cortisol, Aldosterone and ACTH in serum:</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Adrenal Suppression</condition>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.
Remifentanil is stopped before skin closure</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Etomidate</arm_group_label>
    <other_name>Ruijie</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisatracurium</intervention_name>
    <description>Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.
Cisatracurium is stopped before skin closure.</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Etomidate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Etomidate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bispectral index(BIS) monitor</intervention_name>
    <description>BiS is maintained at 40-60 during anesthesia.</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Etomidate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Scheduled for Endotracheal intubated and general anesthesia for general surgery
             patients.

          3. Age 60-75 yrs.

          4. American Society of Anesthesia (ASA) classification I-II.

          5. Expected time of surgery is less than 3 hours. -

        Exclusion Criteria:

          1. Body mass index is more than 36kg/m2.

          2. Systolic blood pressure≥180 mm Hg or &lt;90 mm Hg，diastolic blood pressure≥110 mm Hg or &lt;
             60 mm Hg.

          3. Serious cardiac,cerebral,liver,kidney,lung, endocrine disease or sepsis.

          4. Long term used hormone or adrenal suppression.

          5. Allergy to trial drug or other contraindication.

          6. Difficult airway occurred before,or difficult airway possibly occurred and difficult
             to extubation.

          7. Abuse of narcotic analgesia or suspected.

          8. Neuromuscular diseases.

          9. Mentally unstable or has a mental illness.

         10. Malignant Hyperthermia.

         11. Pregnant or breast-feeding women.

         12. Attended other trial past 30 days. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>He Jiaxuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia, Second Affiliated Hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
    <mesh_term>Atracurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

